GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Gross Profit

Pharmicell Co (XKRX:005690) Gross Profit : ₩13,984 Mil (TTM As of Mar. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Gross Profit?

Pharmicell Co's gross profit for the three months ended in Mar. 2024 was ₩2,385 Mil. Pharmicell Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₩13,984 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Pharmicell Co's gross profit for the three months ended in Mar. 2024 was ₩2,385 Mil. Pharmicell Co's Revenue for the three months ended in Mar. 2024 was ₩10,973 Mil. Therefore, Pharmicell Co's Gross Margin % for the quarter that ended in Mar. 2024 was 21.74%.

Pharmicell Co had a gross margin of 21.74% for the quarter that ended in Mar. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Pharmicell Co was 47.09%. The lowest was 19.09%. And the median was 38.14%.

Warning Sign:

Pharmicell Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -5.9%.


Pharmicell Co Gross Profit Historical Data

The historical data trend for Pharmicell Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Gross Profit Chart

Pharmicell Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,031.19 17,779.29 23,707.97 23,819.59 15,491.96

Pharmicell Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,893.80 4,324.13 3,536.99 3,737.05 2,385.39

Competitive Comparison of Pharmicell Co's Gross Profit

For the Biotechnology subindustry, Pharmicell Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Gross Profit falls into.



Pharmicell Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Pharmicell Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=56227.379 - 40735.416
=15,492

Pharmicell Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=10973.275 - 8587.887
=2,385

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩13,984 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Pharmicell Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2,385 / 10973.275
=21.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Pharmicell Co  (XKRX:005690) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Pharmicell Co had a gross margin of 21.74% for the quarter that ended in Mar. 2024 => Competition eroding margins


Pharmicell Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co (XKRX:005690) Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines